It's easy to be upbeat these days. Stocks have primarily rallied since mid-March. This week found both Warren Buffett and Fed chief Ben Bernanke calling a bottom on the economy.
Don't get greedy, Google (Nasdaq: GOOG).
It's been more than a year since the search-engine giant introduced its Web browser. Google Chrome is slick, quick, and highly praised.
There is apparently no area too remote for the coolness of TiVo (Nasdaq: TIVO).
Here at the Fool, we generally don't pay much attention to Wall Street's stock analysts. If anything, we like to make fun of their endless upgrades and downgrades or simply stick analysts in a cage match against the wisdom of our CAPS crowds.
Sadly, there's no such thing as an ultimate buy signal when it comes to investing in stocks. Identifying companies with the wind at their back takes time, patience, and a good dose of due diligence.
Sadly, there's no such thing as an ultimate buy signal when it comes to investing in stocks. Identifying companies with the wind at their backs takes time, patience, and a good dose of due diligence.
As any graduate of Alcoholics Anonymous knows, the first step to setting out on the proper path is admitting your weakness.
Now that its stock has nearly quintupled since its March low, what can Wynn Resorts (Nasdaq: WYNN) do for an encore?
The latest drug candidate from sanofi-aventis' (NYSE: SNY) was supposed to help people sleep, but it looks as though it'll be keeping management up at night. Yesterday, the drug company said the Food and Drug Administration had turned down the application to market its insomnia drug, Ciltyri.
Having preannounced an earnings collapse back in June, South African energy dynamo Sasol (NYSE: SSL) was unable to surprise the market with its ugly fiscal 2009 results. That said, management offered notable updates aplenty, including a fiscal 2010 forecast that may eventually sap enthusiasm for the shares.